세포 표면 단백질 체학 (Proteomics)에 대한 글리코 펩타이드 캡처

Executive Industry Relevance

Cell surface proteomics faces challenges due to low abundance, hydrophobicity, and complex post-translational modifications, limiting biomarker discovery and drug target validation. This glycopeptide-capture method leverages prevalent N-glycosylation to enrich and analyze surface proteins, enabling improved target confidence and mechanistic de-risking in early discovery. The approach supports translational biomarker identification and portfolio triage by providing quantitative, site-specific glycoproteome data from disease-relevant systems.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by clarifying surface protein expression and glycosylation patterns.
• Operational Value: Supports biological de-risking through functional target validation via enriched glycopeptide identification.
• Predictive Value: Enhances portfolio relevance by providing quantitative data for target prioritization and preclinical decision-making.

Screening & Assay Development

• Assay Readiness: Prepares validated biological systems for downstream workflows by enriching low-abundance surface glycopeptides.
• Reproducibility: Addresses assay standardization through consistent enrichment selectivity (>90%) and quantitative LC-MS outputs.
• Scalability: Enables reliable compound evaluation via platform reuse across cancer, stem cell, and drug toxicity models.

Translational & Preclinical Research

• Disease Relevance: Supports translational biomarker alignment by identifying shed glycoproteins in biofluids linked to pathological processes.
• Preclinical Continuity: Connects discovery through preclinical validation by enabling site-specific glycosylation mapping and quantification.
• Risk-Adjusted Advancement: Informs go/no-go decisions by reducing mechanistic ambiguity in target engagement and pathway modulation.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from hypothesis testing through lead identification, enabling biological de-risking and predictive confidence before preclinical investment.

• Discovery Biology: Supports hypothesis testing and pathway clarification by resolving N-glycoproteome identity, quantity, and glycosylation sites.
• Screening: Delivers assay readiness and quantitative outputs through enriched glycopeptide fractions suitable for LC-MS analysis.
• Analytics: Provides measurable readouts (peptide sequences, glycosylation sites, protein abundance) that enable cross-condition comparison and target ranking.
• Translational Research: Connects to preclinical continuity via biomarker-relevant glycoprotein detection in disease models and biofluids.
• Enterprise Reuse: Functions as a reusable proteomic capability rather than a single-use technique, adaptable across multiple therapeutic areas.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence, target validation, reduction of mechanistic ambiguity in surface protein function.
• Operational Value: Standardization, reproducibility, and scalability of glycopeptide enrichment for LC-MS workflows.
• Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk through early target de-risking.
• Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on quantitative surface proteome data.

Implementation Considerations

• Requires expertise in proteomics, glycobiology, and LC-MS sample preparation.
• Depends on instrumentation for ultracentrifugation, resin-based capture, and nanoLC-MS/MS analysis.
• Necessitates cross-team standardization of digestion, oxidation, and capture protocols for reproducibility.
• Involves adaptation considerations for varying membrane protein abundance and glycosylation density across model systems.
• Limited by low surface membrane protein abundance, requiring larger sample quantities compared to cytosolic protein studies.

Biopharma FAQs